Next Generation Sequencing (NGS) Market to Reach US$ 35.92 Billion by 2033 at 11.6% CAGR; North America Leads with 42% Share - Key Players: Illumina, Thermo Fisher Scientific, Agilent

The global Next Generation Sequencing (NGS) market reached US$ 13.42 billion in 2024 and is projected to reach US$ 35.92 billion by 2033, growing at a CAGR of 11.6% during the forecast period 2025-2033. The market has shown consistent momentum, increasing from US$ 13.12 billion in 2022 to US$ 13.65 billion in 2023, reflecting strong adoption across research and clinical applications.

Next generation sequencing involves advanced workflows such as DNA fragmentation, library preparation, massively parallel sequencing, bioinformatics analysis, and mutation identification. Rising demand for precision medicine, expanding applications in drug discovery and genomics research, and increased availability of NGS platforms and services are driving market growth. North America continues to witness strong demand due to rapid technological advancements and robust research infrastructure, with leading players such as Thermo Fisher Scientific, Illumina, and Bio-Rad Laboratories actively shaping innovation and market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/next-generation-sequencing-ngs-market?sai-v

The Next Generation Sequencing (NGS) Market refers to the global market for advanced DNA and RNA sequencing technologies that enable high-throughput, rapid, and cost-effective genetic analysis for research, diagnostics, and personalized medicine.

Key Developments
✅ December 2025: Leading genomics and life sciences companies unveiled enhanced NGS platforms with increased throughput, improved accuracy, and reduced cost per genome for clinical and research applications.

✅ October 2025: Healthcare systems and cancer centers expanded adoption of NGS for precision oncology, liquid biopsy analysis, and molecular profiling to guide targeted therapy decisions.

✅ September 2025: Advancements in single-cell sequencing and spatial transcriptomics integrated with NGS workflows enhanced discovery of cellular heterogeneity and biomarker identification across complex diseases.

✅ July 2025: Cloud-based bioinformatics solutions with AI/ML-driven analytics gained traction for processing and interpreting high-volume NGS data, improving turnaround times and diagnostic insights.

✅ May 2025: Regulatory agencies in key markets issued updated guidance on clinical validation and quality standards for NGS-based diagnostic assays, influencing adoption in regulated healthcare settings.

✅ March 2025: Collaborative research initiatives expanded deployment of NGS in infectious disease surveillance, antimicrobial resistance monitoring, and population-scale genomic epidemiology studies.

Mergers & Acquisitions
✅ November 2025: A major life sciences tools company acquired an NGS analytics software provider to enhance its end-to-end genomics solution stack from sequencing to interpretation.

✅ August 2025: A global genomics firm partnered with a cloud platform provider to co-develop scalable, secure NGS data management and analytics infrastructure.

✅ June 2025: A biotechnology investor group acquired a single-cell sequencing technology developer to broaden its footprint in advanced NGS applications.

Key Players
Thermo Fisher Scientific Inc. | Agilent Technologies, Inc. | Bio-Rad Laboratories, Inc. | QIAGEN | Eurofins Scientific | Revvity (PerkinElmer Inc.) | Takara Bio Inc. | Illumina Inc. | Alithea Genomics SA | NewBiologix SA | Others

Key Highlights
Thermo Fisher Scientific Inc. - Holds a 23.9% share, driven by its comprehensive genomics and molecular biology portfolio, integrated workflow solutions, and strong adoption across research, clinical, and biopharma laboratories.

Agilent Technologies, Inc. - Holds a 15.8% share, supported by advanced genomics platforms, analytical instruments, and bioinformatics tools widely used in life science research.

Illumina Inc. - Holds a 14.6% share, leveraging leadership in next-generation sequencing technologies that enable high-throughput genomic and transcriptomic analysis.

Bio-Rad Laboratories, Inc. - Holds a 11.7% share, driven by strengths in digital PCR, qPCR, and protein analysis technologies supporting genomic research and diagnostics.

QIAGEN - Holds a 10.4% share, benefiting from expertise in sample preparation, nucleic acid purification, and molecular testing solutions.

Eurofins Scientific - Holds a 8.6% share, supported by its extensive laboratory network, genomics testing services, and strong presence in applied and translational research.

Revvity (PerkinElmer Inc.) - Holds a 6.7% share, leveraging life science reagents, screening technologies, and analytical solutions for genomics and molecular research.

Takara Bio Inc. - Holds a 4.3% share, driven by specialized PCR reagents, sequencing kits, and cell processing technologies with strong uptake in Asia-Pacific markets.

Alithea Genomics SA - Holds a 2.4% share, focused on innovative RNA sequencing library preparation technologies and spatial genomics solutions.

NewBiologix SA - Holds a 1.6% share, specializing in GMP-grade biological reagents and viral vector solutions supporting advanced genomic applications.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=next-generation-sequencing-ngs-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
Rapid adoption of NGS technologies in clinical diagnostics, particularly for oncology profiling, genetic disease screening, and infectious disease detection.

Continuous advancements in sequencing platforms that improve throughput, accuracy, read lengths, and cost-effectiveness.

Growing investment in personalized and precision medicine programs that rely on high-resolution genomic data to tailor therapies and monitor patient responses.

Expanding applications of NGS in research sectors including transcriptomics, epigenetics, microbiome analysis, rare disease research, and pharmacogenomics.

Increasing demand for NGS-based infectious disease surveillance, especially for pathogen identification, outbreak tracking, and antimicrobial resistance detection.

Rising healthcare expenditure and supportive reimbursement policies enabling broader clinical integration of genomic sequencing.

Development of cloud-based bioinformatics solutions and AI/ML-enhanced analytics to handle large-scale genomic datasets and extract actionable insights.

Growing collaborations between academic institutions, biotech firms, and healthcare providers to accelerate translational research and clinical implementation.

Industry Developments
Launch of next-generation NGS platforms with higher throughput (e.g., whole-genome and whole-exome sequencing), lower per-sample costs, and improved accuracy.

Expansion of targeted sequencing panels tailored for specific disease pathways (e.g., cancer panels, inherited disease panels, pharmacogenomic assays).

Strategic partnerships between NGS instrument manufacturers and clinical laboratory networks to broaden market access and streamline workflows.

Integration of advanced sample preparation kits, automated library preparation systems, and microfluidics to improve lab efficiency.

Increased investments, mergers, acquisitions, and licensing initiatives to consolidate technology portfolios and scale up operations.

Development of cloud-based and AI-driven bioinformatics pipelines for rapid sequence interpretation, variant annotation, and data sharing.

Growth of decentralized and point-of-care sequencing initiatives for infectious disease monitoring and rapid clinical decision support.

Regulatory approvals and guideline updates enhancing clinical utility and standardization of NGS assays across diagnostics settings.

Regional Insights
North America - 42% share: "Driven by strong presence of key NGS technology providers, extensive clinical genomics adoption in oncology and rare diseases, robust research infrastructure, and supportive reimbursement frameworks."

Europe - 27% share: "Supported by growing precision medicine initiatives, expanding genomic research collaborations, public-private funding for NGS applications, and increasing clinical uptake."

Asia Pacific - 24% share: "Fueled by expanding healthcare infrastructure, rising genomics research funding, growing infectious disease sequencing needs, and increasing adoption of NGS solutions in China, Japan, and India."

Latin America - 5% share: "Boosted by improving genomic medicine awareness, expanding research activities, and gradual adoption of NGS technologies in clinical and academic settings."

Middle East & Africa - 2% share: "Driven by emerging genomic research initiatives, investments in healthcare modernization, and growing focus on infectious disease surveillance and genetic testing."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/next-generation-sequencing-ngs-market?sai-v

Key Segments

By Product Type
Consumables account for the largest share of the NGS market, driven by recurring demand for reagents, kits, and sequencing cartridges required for each run. Instruments hold a significant share, supported by continuous technological advancements, higher throughput systems, and expanding installation bases in clinical and research settings. Software and services represent a growing segment, driven by the increasing need for bioinformatics, data analysis, storage, and interpretation of large genomic datasets.

By Application
Research applications dominate the market, supported by extensive use of NGS in genomics, transcriptomics, epigenomics, and functional genomics studies. Clinical diagnostics represent a rapidly growing segment, driven by rising adoption of NGS in oncology, rare disease diagnosis, and reproductive health testing. Drug discovery and development hold a notable share, supported by the use of NGS for target identification, biomarker discovery, and companion diagnostics. Other applications, including agriculture, microbiology, and forensics, contribute steadily to market expansion.

By Technology
Sequencing by synthesis (SBS) holds the largest share, driven by its high accuracy, scalability, and widespread adoption across research and clinical workflows. Ion semiconductor sequencing maintains a steady presence due to its faster run times and suitability for targeted sequencing. Single-molecule real-time (SMRT) sequencing is witnessing strong growth, driven by its ability to generate long reads for structural variant analysis and de novo genome assembly. Nanopore sequencing is expanding rapidly, supported by portability, real-time analysis, and decreasing costs. Other emerging technologies continue to gain traction through ongoing innovation.

By End User
Academic and research institutes represent the largest end-user segment, driven by sustained funding for genomic research and large-scale sequencing projects. Clinical laboratories and hospitals are witnessing rapid growth, supported by increasing integration of NGS into routine diagnostic workflows. Pharmaceutical and biotechnology companies hold a significant share, driven by applications in drug discovery, clinical trials, and precision medicine. Other end users, including contract research organizations (CROs), agricultural institutes, and forensic laboratories, contribute to overall market growth.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.